Cellectar Biosciences CLRB
$ 0.26
9.74%
Quarterly report 2024-Q3
added 11-18-2024
Cellectar Biosciences Balance Sheet 2011-2024 | CLRB
Annual Balance Sheet Cellectar Biosciences
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-9.01 M | -19.3 M | -35.4 M | -57.2 M | -10.1 M | -13.3 M | -10 M | -11.4 M | -3.53 M | -8.97 M | -1.97 M | -4.22 M | -5.05 M |
Long Term Debt |
494 K | 553 K | 166 K | - | - | - | - | - | 86.6 K | 330 K | 450 K | 450 K | 450 K |
Long Term Debt Current |
59 K | 50.8 K | 135 K | 120 K | 106 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 422 K | 171 K | 2.21 K | 152 K | 244 K | 489 K | 593 K | 587 K | 578 K |
Total Current Liabilities |
25.4 M | 11.5 M | 3.99 M | 3.56 M | 2.77 M | 1.62 M | 2.11 M | 1.63 M | 5.7 M | 6.23 M | 4.52 M | 733 K | 504 K |
Total Liabilities |
25.9 M | 12.1 M | 4.16 M | 302 K | 3.19 M | 1.79 M | 2.12 M | 1.78 M | 5.95 M | 2.67 M | 5.12 M | 1.32 M | 1.08 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-203 M | -160 M | -151 M | - | -112 M | -97.6 M | -84.3 M | -70.8 M | -64.6 M | -59.2 M | -51.1 M | -40.3 M | -31.5 M |
Total Assets |
12.1 M | 21.6 M | 37.2 M | 58.7 M | 12.3 M | 15.1 M | 12.9 M | 15.3 M | 7.6 M | 13.4 M | 6.82 M | 11.5 M | 10.6 M |
Cash and Cash Equivalents |
9.56 M | 19.9 M | 35.7 M | 57.2 M | 10.6 M | 13.3 M | 10 M | 11.4 M | 3.86 M | 9.42 M | 2.42 M | 4.68 M | 5.51 M |
Book Value |
-13.8 M | 9.54 M | 33 M | 58.4 M | 9.06 M | 13.3 M | 10.8 M | 13.5 M | 1.65 M | 10.7 M | 1.7 M | 10.2 M | 9.48 M |
Total Shareholders Equity |
-15.2 M | 8.15 M | 33 M | 54.8 M | 9.06 M | 13.3 M | 10.8 M | 13.5 M | 1.65 M | 6.7 M | 1.7 M | 10.2 M | 9.48 M |
All numbers in USD currency
Quarterly Balance Sheet Cellectar Biosciences
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
432 K | 454 K | 474 K | 494 K | 513 K | 531 K | 548 K | 553 K | 53.8 K | - | 130 K | 166 K | 202 K | 236 K | 269 K | 302 K | 302 K | 302 K | 302 K | 422 K | 422 K | 422 K | 422 K | - | - | - | - | - | - | - | - | - | - | - | - | 330 K | - | - | - | 450 K | - | 3.8 M | 3.77 M | 450 K | - | - | - | 450 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 302 K | 517 K | 548 K | 393 K | 422 K | 422 K | 422 K | 422 K | 171 K | 171 K | 171 K | 171 K | 2.21 K | 2.21 K | 2.21 K | 2.21 K | 152 K | 152 K | 152 K | 152 K | 244 K | 244 K | 244 K | 244 K | 489 K | 489 K | 489 K | 489 K | 593 K | 593 K | 593 K | 593 K | 587 K | 587 K | 587 K | 587 K | 578 K | 578 K | 578 K | 578 K |
Total Liabilities |
20.7 M | 15.6 M | 16.7 M | 25.9 M | 17 M | 6.98 M | 7.5 M | 6.08 M | 6.57 M | - | 4.78 M | 4.16 M | 3.37 M | 3.75 M | 5.29 M | 3.86 M | 3.86 M | 3.86 M | 3.86 M | 3.19 M | 3.19 M | 3.19 M | 3.19 M | 1.79 M | 1.79 M | 1.79 M | 1.79 M | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 5.95 M | 5.95 M | 5.95 M | 5.95 M | 6.72 M | 6.72 M | 6.72 M | 6.72 M | 5.12 M | 5.12 M | 5.12 M | 5.12 M | 1.32 M | 1.32 M | 1.32 M | 1.32 M | 1.08 M | - | 1.08 M | 1.08 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-245 M | -230 M | -239 M | -203 M | -210 M | -196 M | - | -179 M | -172 M | - | - | -151 M | -145 M | -139 M | -133 M | -127 M | -127 M | -127 M | -127 M | -112 M | -112 M | -112 M | -112 M | -97.6 M | -97.6 M | -97.6 M | -97.6 M | -84.3 M | -84.3 M | -84.3 M | -84.3 M | -70.8 M | -70.8 M | -70.8 M | -70.8 M | -64.6 M | -64.6 M | -64.6 M | -64.6 M | -59.1 M | -59.1 M | -59.1 M | -59.1 M | -51.1 M | -51.1 M | -51.1 M | - | - | - | - | - | - | - | - | - |
Total Assets |
37.3 M | 29.4 M | 42.9 M | 12.1 M | 21.6 M | 6.51 M | 14.8 M | 21.6 M | 19.3 M | - | 32 M | 37.2 M | 42 M | 47.7 M | 55.1 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 6.82 M | 6.82 M | 6.82 M | 6.82 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M |
Cash and Cash Equivalents |
34.3 M | 25.9 M | 40 M | 9.56 M | 19 M | 5.15 M | 12.7 M | 19.9 M | 17.8 M | 24.8 M | 30.6 M | 35.7 M | 40.3 M | 46.8 M | 53.6 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 10 M | 10 M | 10 M | 10 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 3.91 M | 3.86 M | 3.86 M | 3.86 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 4.68 M | 4.68 M | 4.68 M | 4.68 M | 5.51 M | 5.51 M | 5.51 M | 5.51 M |
Book Value |
16.5 M | 13.8 M | 26.2 M | -13.8 M | 4.57 M | -467 K | 7.33 M | 15.5 M | 12.8 M | - | 27.2 M | 33 M | 38.6 M | 44 M | 49.8 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 1.65 M | 1.65 M | 1.65 M | 1.65 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 9.48 M | 10.6 M | 9.48 M | 9.48 M |
Total Shareholders Equity |
15.2 M | 12.4 M | 26.2 M | -15.2 M | -28 M | -8.39 M | 7.33 M | 15.5 M | 12.8 M | 20.2 M | 27.2 M | 33 M | 38.6 M | 44 M | 49.8 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 9.06 M | 9.06 M | 9.06 M | 9.06 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 1.65 M | 1.65 M | 1.65 M | 1.65 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 9.48 M | 9.48 M | 9.48 M | 9.48 M |
All numbers in USD currency